Author:
Chi Kim N.,Chia Stephen K.,Dixon Ross,Newman Michael J.,Wacher Vince J.,Sikic Branimir,Gelmon Karen A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference10 articles.
1. Ling, V: Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40(Suppl): S3–S8, 1997
2. Cordon-Carlo C, O’Brien JP, Boccia J, Casals D, Bertino J, Melamed MR: Expression of the multidrug resistance gene product (p-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277–1287, 1990
3. Sikic BI: Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 34: S40–S47, 1997 (suppl 5)
4. Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP: Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: A gynecologic Oncology Group Study. J Clin Oncol 19: 2975–2982, 2001
5. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD: Safety and efficacy of the multidrug resistance inhibitor incel (Biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 8: 670–678, 2002
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献